www.streetinvesting.com: Market Review on Inhibitex Inc

Dec 14, 2007 (M2 PRESSWIRE via COMTEX) -- INHX | charts | news | PowerRating -- Investors need to turn to the markets these days if even to simply counter the depreciation of their hard earned wealth. Consumer inflation surged by the largest amount in more than two years in November led, by a huge jump in gasoline prices. Inflation also hit home with big increases in the cost of clothing, airline tickets and prescription drugs. The 0.8 percent rise in consumer prices was worse than the 0.6 percent advance that economists had expected. With one month to go, inflation in 2007 is rising at an annual rate of 4.2 percent! This well outweighed the 2.5 percent increase in 2006. There is worry that the jump in energy costs will leave consumers with less money to spend on other items, worsening the slowdown in economic growth that is already manifesting this nation. Inhibitex Inc (NASDAQ:INHY) traded up 1% early Friday morning, with average volume.

Our research resources have been aimed towards the US Large Caps and the various prospective companies therein. Ihibitex Inc was among those that we have been closely examining due to their recent news and trading patterns.

Dec 14th 2007, Inhibitex, Inc. a biopharmaceutical company focused on the development of products to treat and prevent serious infectious diseases, announced today that it has completed its initial Phase I clinical trial of FV-100, a nucleoside analogue being developed to treat shingles. The blinded, placebo-controlled single ascending dose study, which was conducted in the United States under an exploratory Investigational New Drug Application evaluated the safety and pharmacokinetics of three oral doses of FV-100 in healthy volunteers. Each of the three dose cohorts consisted of six subjects that received FV-100 and two that received placebo.

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the development of products that can treat or prevent serious infections. In addition to its emerging antiviral pipeline that includes FV-100, HIV integrase inhibitors, HCV polymerase inhibitors and a series of compounds to address cytomegalovirus infections, the Company has several development programs and collaborations based upon its proprietary MSCRAMM protein platform. These include Aurexis, a humanized monoclonal antibody being developed for the treatment of serious Staphylococcus aureus bloodstream infections for which the Company has completed a Phase II clinical trial, as well as license agreements with Wyeth for the development of staphylococcal vaccines and 3M for the development of diagnostics.

With the recent climax remodeling the market temporarily and taking investors on a roller-coaster ride, Streetinvesting.com will keep track of the performance and future news release of this company. Our research team will bring you any news or updates about Inhibitex Inc as they come into the public realm in the coming weeks and months.

To continue with the more in-depth analysis, please visit www.streetinvesting.com for a complimentary subscription to access this report and other related articles. Please note that membership does not require credit card information.

All material herein was prepared by Streetinvesting.com, (Street Investing) based upon information believed to be reliable. The information contained herein is not guaranteed by Streetinvesting.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Streetinvesting.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Streetinvesting.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Streetinvesting.com's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those share's rise in value.

Streetinvesting.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Streetinvesting.com undertakes no obligation to update such statements.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index